Opportunities and challenges of immunotherapy for patients with resectable and potentially resectable stage Ⅲ non-small cell lung cancerOA
Opportunities and challenges of immunotherapy for patients with resectable and potentially resectable stage Ⅲ non-small cell lung cancer
Yuzhen Cui;Jingdong Xu;Junxu Wen;Jianfeng Peng;Jiangao Ren;Ailing Liu;Xiangjiao Meng;Zhaoqin Huang;Anwen Liu
Nanchang University Queen Mary School,Nanchang 330031,China||Queen Mary University of London,London E1 4NS,UKNanchang University Queen Mary School,Nanchang 330031,China||Queen Mary University of London,London E1 4NS,UKDepartment of Radiation Oncology,Shandong Cancer Hospital and Institute,Shandong First Medical University and Shandong Academy of Medical Sciences,Jinan 250117,ChinaDepartment of Radiation Oncology,Shandong Cancer Hospital and Institute,Shandong First Medical University and Shandong Academy of Medical Sciences,Jinan 250117,ChinaNanchang University Queen Mary School,Nanchang 330031,China||Queen Mary University of London,London E1 4NS,UKDepartment of Radiation Oncology,Shandong Cancer Hospital and Institute,Shandong First Medical University and Shandong Academy of Medical Sciences,Jinan 250117,ChinaDepartment of Radiation Oncology,Shandong Cancer Hospital and Institute,Shandong First Medical University and Shandong Academy of Medical Sciences,Jinan 250117,ChinaDepartment of Radiology,Shandong Provincial Hospital Affiliated to Shandong First Medical University,Jinan 250021,ChinaDepartment of Oncology,The Second Affiliated Hospital of Nanchang University,Nanchang 330006,China
Non-small cell lung cancerimmunotherapychemotherapyradiotherapyresectablepotentially resectablebiomarkers
Non-small cell lung cancerimmunotherapychemotherapyradiotherapyresectablepotentially resectablebiomarkers
《癌症生物学与医学（英文版）》 2026 (6)
865-887,23
This work was supported by a grant from the Natural Science Foundation of Shandong Province(Grant No.ZR2023LZL001).
评论